Patients are receiving a combination of Nektar's CD122-preferential interleukin-2 (IL-2) pathway agonist bempegaldesleukin (bempeg) and Vaccibody's personalized neoantigen cancer vaccine Vb10.Neo. Adding bempeg to Vb10.Neo is intended to drive maximal expansion of vaccine-induced neoantigen-specific T cells for the treatment of cancer, according to the companies.

The vaccine is designed to specifically activate the patient's immune system to tumor-specific antigens while bempeg will expand and proliferate tumor antigen specific T cells in the periphery and the tumor microenvironment.

Direct Biologics begins phase II trial for COVID-19 ExoFlo therapy
Regenerative medical products manufacturer Direct Biologics has won approval from the U.S. Food and Drug Administration to study its ExoFlo therapy in...

Researchers discuss progress toward personalized cancer vaccines
Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized...

New consortium formed to develop cell-based cancer vaccines
A new consortium has been formed to increase access to cell-based cancer vaccines by using single-use technology to develop and manufacture dendritic...